The insulin receptor substrate-1: a biomarker for cancer?
This review focuses on IRS-1 and the evidence of its role in cell transformation. The literature strongly suggests that IRS-1 should be considered a biomaker for cancers susceptible to IGF-IR targeting. In addition, I would like to propose that IRS-1 may have a more general role in cancer, and could be considered as a protein having the opposite effect of tumor suppressors, a sort of anti-p53 molecule.
Baserga
Renato
R
Thomas Jefferson University, Kimmel Cancer Center, 233 S. 10th Street, 624 BLB, Philadelphia, PA 19107, USA. r_baserga@mail.jci.tju.edu
D000818:Animals; D000970:Antineoplastic Agents / Q000627:therapeutic use; D014408:Biomarkers, Tumor / Q000235:genetics*; D002471:Cell Transformation, Neoplastic / Q000235:genetics; D016503:Drug Delivery Systems / Q000379:methods; D006801:Humans; D055504:Insulin Receptor Substrate Proteins / Q000235:genetics / Q000378:metabolism / Q000502:physiology*; D035683:MicroRNAs / Q000627:therapeutic use; D009369:Neoplasms / Q000175:diagnosis* / Q000188:drug therapy / Q000235:genetics*; D000081082:Phosphoinositide-3 Kinase Inhibitors; D011485:Protein Binding
D000970:Antineoplastic Agents; D014408:Biomarkers, Tumor; D055504:Insulin Receptor Substrate Proteins; D035683:MicroRNAs; D000081082:Phosphoinositide-3 Kinase Inhibitors